Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma
NCT05282433
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
45
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival
Interventions
DRUG:
Surufatinib
Sponsor
Zhongnan Hospital